Drug intelligence / Profile preview

REC 0482

Development stage: Unknown
Lead developer: Recordati Rare Diseases
Modality: Small Molecules
Administration: Intraprostatic

Overview

REC 0482 (also known as NX-1207) is an innovative small molecule developed for the treatment of benign prostatic hyperplasia (BPH). It is administered via a single transrectal ultrasound (TRUS)-guided intraprostatic injection to patients with lower urinary tract symptoms (LUTS) associated with BPH who are not adequately controlled by medical therapy. The drug was being prepared for a pivotal European Phase III clinical trial following a successful Scientific Advice meeting with the European Medicines Agency (EMA), with activities initiated in early 2012 by Recordati S.p.A.[2]

Beyond the preview

Go deeper on REC 0482.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REC 0482.

Explore the full profile